AMS IS THE INDUSTRY LEADER IN STRATEGIC INTELLIGENCE SOFTWARE FOR COMBATTING EMERGING HIGH-COST CLAIM ISSUES
What We Do:
AMS provides tech-enabled healthcare solutions delivering crucial insight into catastrophic diagnoses, specialty pharmaceutical, and implant price transparency by means of clinically vetted, predictive financial analytics with near real-time data.
Who We Serve:
AMS serves multiple stakeholders in the medical claims payment chain, including commercial and governmental payers, Stop Loss and Reinsurance Carriers, MGUs, Medical Management Firms, Health Plans, TPAs, HMOs, Taft-Hartley Plans, workers compensation, and auto medical carriers.
WHO IS USING THE PREDICT SUITE
THE PREDICT SUITE
AMS’ Web-based directories that allow
clients to predict, evaluate and manage high dollar healthcare claims.
PREDICT
Predict costs and clinical treatments for high dollar diagnoses with an on demand decision support solution delivering in-depth clinical information, empirical insight and key financial analytics.
EVALUATE
Evaluate cost data, FDA approved indications, notable off-label usage, adult/pediatric dosing regimens, manufacturer rebates, specialty drug coding and price trends.
MANAGE
Manage highly inflated implant claims by leveraging detailed clinical and financial metrics with the only online, fully- transparent implant cost directory in the industry.
PREDICT SUITE MEMBERSHIP HAS ITS BENEFITS
10+M
Dollars Saved Annually
We have saved tens of millions of dollars for our clients and members
99%
Members
Retained
We have retained 99% of our members
750+
Sub Specialty
Physicians
750+ specialty physicians in our peer review panel
100s
Weekly Hours
Saved
We have saved our clients and members 100s of weekly hours in research and underwriting
AMS Blog
-
Using a new approach, scientists have located a compound that stops the spread of breast, pancreatic, and prostate cancers in mice. The compound — which they call metarrestin — destroys a unique structure inside the nucleus of cancer cells that can spread and form new tumors. A paper on the work — in which researchers… Read More »
-
Insys Update: Stunning Numbers, Devastating Results
May 21, 2018
By: Jason Marcewicz | Content and Communications Specialist | Advanced Medical Strategies The pharmaceutical company Insys Therapeutics has been in the news a lot recently—and for all the wrong reasons. Last September AMS reported about Insys’ schemes to sell more of their pain drug Subsys to unwitting physicians. Now, it seems that Insys didn’t just… Read More »